Exabis Library
Welcome to the e-CCO Library!
P612: Exclusive enteral nutrition in adults with active Crohn's disease is associated with decreased disease activity
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P612: Immunosuppressive co-treatment with infliximab and adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P612: Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P612: Long-term outcomes of treatment intervention according to the severity of small bowel capsule endoscopy findings in patients with Crohn’s disease: A Japanese single-centre cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P612: Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P612: Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P613: Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P613: Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-alpha inhibitors and conventional immunosuppressants
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P613: Predictors of treatment persistence in ulcerative colitis patients treated with golimumab: A multicentre cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P613: Social Media Analytics for Inflammatory Bowel Disease – What Are We Missing?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P613: Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P613: Tacrolimus as rescue therapy for steroid-dependent/steroid refractory ulcerative colitis: experience from tertiary referral centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P614 Micro-fragmented autologous adipose tissue injection for fistula-in-ano (MAATIFA) in patients with Crohn’s disease: A prospective observational study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P614: A strategy to solve complexity of physician diagnosis using a mixture of Patient Reports and Provider Reports: A Case Study of Crohn’s Disease Phenotypes
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P614: Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P614: Pregnancy outcomes in women with IBD treated with biosimilar infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P614: Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P614: Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P614: The utility as a biomarker of faecal calprotectin for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis treatment in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM